Clinical Studies Regarding Product. Except as required by applicable Regulatory Requirements or as may be necessary to maintain the Registration for the Product or Phase IV clinical studies with respect to the Product in respect of any indication covered by the FDA-approved label for the Product, any right of RELIANT to initiate any clinical or pre-clinical studies relating to the Product shall be subject to the Development Intention Notice and Development Objection Notice procedures set forth under Section 2.3.
Appears in 6 contracts
Samples: Agreement, Agreement (Reliant Pharmaceuticals, Inc.), Agreement (Reliant Pharmaceuticals, Inc.)
